Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study

This publication published in Journal of Pharmaceutical Health Services Research represents peer-reviewed research in Humans, Quality of Life, Angioedemas, Hereditary directly relevant to Aimwell’s evidence intelligence infrastructure. It contributes to the FHIN network’s knowledge base on Humans and supports data-driven clinical decision making for Aimwell member organizations.